Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PROK
PROK | US
1.94
USD-0.06
-3.00%
PROK | US
Loading StockChartView...
About PROK
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
1.94
Open
1.99
High
2.02
Low
1.93
ProKidney Corp. a clinical-stage biotechnology company provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT) an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem North Carolina.
View LessPROK | US
Risk
81.4
Sharpe
0.21
Luna's Score
39/100
Recommendation
Sell
Luna says (PROK | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
75.6%1 month
81.4%3 months
74.6%6 months
75.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
91.32
Debt to equity
-0.01
Debt to assets
0.01
Ent. to EBITDA
2.13
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-149.44M
MarketCap
1.78B
MarketCap(USD)
1.78B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-29.60
Short ratio
8.41
Short perc.
8.71
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.35
Range1M
0.63
Range3M
1.04
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.63
Price X volume
1.36M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.13 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 91.32 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 74.59 | 72.80 | Par |
| Debt to Equity | -0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.78B | 3.66B | Emerging |
